Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Garde

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
NPJ Vaccines|March 21, 2025
Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccinesChristian Garde, Michail A Pavlidis, Pablo Garces, et al.
Blood|March 5, 2015
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticatorSimon Husby, Ulrik Ralfkiaer, Christian Garde, et al.
Oncoimmunology|January 17, 2022
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanomaSofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, et al.
British Journal of Haematology|July 6, 2016
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateauChristian W Eskelund, Arne Kolstad, Mats Jerkeman, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
NPJ Vaccines|March 21, 2025
Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccinesChristian Garde, Michail A Pavlidis, Pablo Garces, et al.
Blood|March 5, 2015
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticatorSimon Husby, Ulrik Ralfkiaer, Christian Garde, et al.
Oncoimmunology|January 17, 2022
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanomaSofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, et al.
British Journal of Haematology|July 6, 2016
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateauChristian W Eskelund, Arne Kolstad, Mats Jerkeman, et al.
Pageof 3